Donald Andrew Belcher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Donald Andrew Belcher has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Andre Francis Palmer
The Ohio State University
9 shared publications - Ivan Susin Pires
Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology 500 Main Street Cambridge MA 02139 USA
5 shared publications Jin Hyen Baek
Laboratory of Biochemistry and Vascular Biology, Division of Hematology, Center for Biologics Evaluation and Research Food and Drug Administration Silver Spring Maryland
3 shared publications- Pedro Cabrales
University of California San Diego
3 shared publications Abraham K. Badu‐Tawiah
Department of Chemistry and Biochemistry The Ohio State University Columbus Ohio
2 shared publications- Alexander Thomas Williams
Department of Bioengineering, University of California, San Diego, La Jolla, CA, 92093-0412, United States of America
2 shared publications
Latest Publications
- Open Access
- 3 October 2022
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (12) , 3447-3461
Pilot scale production and characterization of next generation high molecular weight and tense quaternary state polymerized human hemoglobin
Polymerized human hemoglobin (PolyhHb) is being studied as a possible red blood cell (RBC) substitute for use in scenarios where blood is not available. While the oxygen (O2) carrying capacity of PolyhHb makes it appealing as an O2 therapeutic, the commercial PolyhHb PolyHeme® (Northfield Laboratories Inc.) was never approved for clinical use due to the presence of large quantities of low molecular weight (LMW) polymeric hemoglobin (Hb) species (0.2 µm and <500 kDa) in the material, to create a product that should be safer for transfusion. Therefore, to enable future large animal studies and eventual human clinical trials, PolyhHb synthesis and purification processes need to be scaled up to the pilot scale. Hence in this study, we describe the pilot scale synthesis and purification of PolyhHb. Characterization of pilot scale PolyhHb showed that PolyhHb could be successfully produced to yield biophysical properties conducive for its use as an RBC substitute. Size exclusion high performance liquid chromatography showed that pilot scale PolyhHb yielded a high molecular weight Hb polymer containing a small percentage of LMW Hb species (<500 kDa). Additionally, the auto‐oxidation rate of pilot scale PolyhHb was even lower than that of previous generations of PolyhHb. Taken together, these results demonstrate that PolyhHb has the ability to be seamlessly manufactured at the pilot scale to enable future large animal studies and clinical trials.
- 3 October 2022
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 119 (12) , 3447-3461
Open AccessPilot scale production and characterization of next generation high molecular weight and tense quaternary state polymerized human hemoglobin
Polymerized human hemoglobin (PolyhHb) is being studied as a possible red blood cell (RBC) substitute for use in scenarios where blood is not available. While the oxygen (O2) carrying capacity of PolyhHb makes it appealing as an O2 therapeutic, the commercial PolyhHb PolyHeme® (Northfield Laboratories Inc.) was never approved for clinical use due to the presence of large quantities of low molecular weight (LMW) polymeric hemoglobin (Hb) species (0.2 µm and <500 kDa) in the material, to create a product that should be safer for transfusion. Therefore, to enable future large animal studies and eventual human clinical trials, PolyhHb synthesis and purification processes need to be scaled up to the pilot scale. Hence in this study, we describe the pilot scale synthesis and purification of PolyhHb. Characterization of pilot scale PolyhHb showed that PolyhHb could be successfully produced to yield biophysical properties conducive for its use as an RBC substitute. Size exclusion high performance liquid chromatography showed that pilot scale PolyhHb yielded a high molecular weight Hb polymer containing a small percentage of LMW Hb species (<500 kDa). Additionally, the auto‐oxidation rate of pilot scale PolyhHb was even lower than that of previous generations of PolyhHb. Taken together, these results demonstrate that PolyhHb has the ability to be seamlessly manufactured at the pilot scale to enable future large animal studies and clinical trials.
- Open Access
- 20 August 2020
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 16 (8) , e1008157
Tumor vascular status controls oxygen delivery facilitated by infused polymerized hemoglobins with varying oxygen affinity
Oxygen (O2) delivery facilitated by hemoglobin (Hb)-based O2 carriers (HBOCs) is a promising strategy to increase the effectiveness of chemotherapeutics for treatment of solid tumors. However, the heterogeneous vascular structures present within tumors complicates evaluating the oxygenation potential of HBOCs within the tumor microenvironment. To account for spatial variations in the vasculature and tumor tissue that occur during tumor growth, we used a computational model to develop artificial tumor constructs. With these simulated tumors, we performed a polymerized human hemoglobin (hHb) (PolyhHb) enhanced oxygenation simulation accounting for differences in the physiologic characteristics of human and mouse blood. The results from this model were used to determine the potential effectiveness of different treatment options including a top load (low volume) and exchange (large volume) infusion of a tense quaternary state (T-State) PolyhHb, relaxed quaternary state (R-State) PolyhHb, and a non O2 carrying control. Principal component analysis (PCA) revealed correlations between the different regimes of effectiveness within the different simulated dosage options. In general, we found that infusion of T-State PolyhHb is more likely to decrease tissue hypoxia and modulate the metabolic rate of O2 consumption. Though the developed models are not a definitive descriptor of O2 carrier interaction in tumor capillary networks, we accounted for factors such as non-uniform vascular density and permeability that limit the applicability of O2 carriers during infusion. Finally, we have used these validated computational models to establish potential benchmarks to guide tumor treatment during translation of PolyhHb mediated therapies into clinical applications. High rates of oxygen consumption and abnormal vascularization lead to low oxygen levels within solid tumors. The lack of oxygen results in resistance to chemotherapies and increased rates of cancer progression. Hemoglobin-based oxygen carriers have the potential to increase the amount of oxygen delivered to tumors, which may make chemotherapies more effective. Unfortunately, translating experimental results from mice to humans is complicated by allometric scaling between mice and humans. To predict how these therapies may perform differently between human and murine systems, we computationally predicted how hemoglobin-based oxygen delivery varies between the two organisms. Our model accounts for how variations in the tumor vascular network impact the performance of hemoglobin-based oxygen carriers. This model also allows us to assess how the oxygen affinity of hemoglobin-based oxygen carriers affects the oxygenation of hypoxic tissue. The results of these models help us predict how results from murine models may translate to humans. Also, our models help to highlight what clinically-measurable tumor properties should be measured to predict the effectiveness of hemoglobin-based oxygen carriers in biological systems.
- 20 August 2020
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 16 (8) , e1008157
Open AccessTumor vascular status controls oxygen delivery facilitated by infused polymerized hemoglobins with varying oxygen affinity
Oxygen (O2) delivery facilitated by hemoglobin (Hb)-based O2 carriers (HBOCs) is a promising strategy to increase the effectiveness of chemotherapeutics for treatment of solid tumors. However, the heterogeneous vascular structures present within tumors complicates evaluating the oxygenation potential of HBOCs within the tumor microenvironment. To account for spatial variations in the vasculature and tumor tissue that occur during tumor growth, we used a computational model to develop artificial tumor constructs. With these simulated tumors, we performed a polymerized human hemoglobin (hHb) (PolyhHb) enhanced oxygenation simulation accounting for differences in the physiologic characteristics of human and mouse blood. The results from this model were used to determine the potential effectiveness of different treatment options including a top load (low volume) and exchange (large volume) infusion of a tense quaternary state (T-State) PolyhHb, relaxed quaternary state (R-State) PolyhHb, and a non O2 carrying control. Principal component analysis (PCA) revealed correlations between the different regimes of effectiveness within the different simulated dosage options. In general, we found that infusion of T-State PolyhHb is more likely to decrease tissue hypoxia and modulate the metabolic rate of O2 consumption. Though the developed models are not a definitive descriptor of O2 carrier interaction in tumor capillary networks, we accounted for factors such as non-uniform vascular density and permeability that limit the applicability of O2 carriers during infusion. Finally, we have used these validated computational models to establish potential benchmarks to guide tumor treatment during translation of PolyhHb mediated therapies into clinical applications. High rates of oxygen consumption and abnormal vascularization lead to low oxygen levels within solid tumors. The lack of oxygen results in resistance to chemotherapies and increased rates of cancer progression. Hemoglobin-based oxygen carriers have the potential to increase the amount of oxygen delivered to tumors, which may make chemotherapies more effective. Unfortunately, translating experimental results from mice to humans is complicated by allometric scaling between mice and humans. To predict how these therapies may perform differently between human and murine systems, we computationally predicted how hemoglobin-based oxygen delivery varies between the two organisms. Our model accounts for how variations in the tumor vascular network impact the performance of hemoglobin-based oxygen carriers. This model also allows us to assess how the oxygen affinity of hemoglobin-based oxygen carriers affects the oxygenation of hypoxic tissue. The results of these models help us predict how results from murine models may translate to humans. Also, our models help to highlight what clinically-measurable tumor properties should be measured to predict the effectiveness of hemoglobin-based oxygen carriers in biological systems.
- Open Access
- 9 July 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-12
Polymerized human hemoglobin facilitated modulation of tumor oxygenation is dependent on tumor oxygenation status and oxygen affinity of the hemoglobin-based oxygen carrier
Administration of hemoglobin-based oxygen carriers (HBOCs) into the systemic circulation is a potential strategy to relieve solid tumor hypoxia in order to increase the effectiveness of chemotherapeutics. Previous computational analysis indicated that the oxygen (O2) status of the tumor and HBOC O2 affinity may play a role in increased O2 delivery to the tumor. However, no study has experimentally investigated how low- and high-affinity HBOCs would perform in normoxic and hypoxic tumors. In this study, we examined how the HBOC, polymerized human hemoglobin (PolyhHb), in the relaxed (R) or tense (T) quaternary state modulates O2 delivery to hypoxic (FME) and normoxic (LOX) human melanoma xenografts in a murine window chamber model. We examined microcirculatory fluid flow via video shearing optical microscopy, and O2 distributions via phosphorescence quenching microscopy. Additionally, we examined how weekly infusion of a 20% top-load dose of PolyhHb influences growth rate, vascularization, and regional blood flow in the FME and LOX tumor xenografts. Infusion of low-affinity T-state PolyhHb led to increased tissue oxygenation, decreased blood flow, decreased tumor growth, and decreased vascularization in hypoxic tumors. However, infusion of both T-state and R-state PolyhHbs led to worse outcomes in normoxic tumors. Of particular concern was the high-affinity R-state PolyhHb, which led to no improvement in hypoxic tumors and significantly worsened outcomes in normoxic tumors. Taken together, the results of this study indicate that the tumor O2 status is a primary determinant of the potency and outcomes of infused PolyhHb.
- 9 July 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-12
Open AccessPolymerized human hemoglobin facilitated modulation of tumor oxygenation is dependent on tumor oxygenation status and oxygen affinity of the hemoglobin-based oxygen carrier
Administration of hemoglobin-based oxygen carriers (HBOCs) into the systemic circulation is a potential strategy to relieve solid tumor hypoxia in order to increase the effectiveness of chemotherapeutics. Previous computational analysis indicated that the oxygen (O2) status of the tumor and HBOC O2 affinity may play a role in increased O2 delivery to the tumor. However, no study has experimentally investigated how low- and high-affinity HBOCs would perform in normoxic and hypoxic tumors. In this study, we examined how the HBOC, polymerized human hemoglobin (PolyhHb), in the relaxed (R) or tense (T) quaternary state modulates O2 delivery to hypoxic (FME) and normoxic (LOX) human melanoma xenografts in a murine window chamber model. We examined microcirculatory fluid flow via video shearing optical microscopy, and O2 distributions via phosphorescence quenching microscopy. Additionally, we examined how weekly infusion of a 20% top-load dose of PolyhHb influences growth rate, vascularization, and regional blood flow in the FME and LOX tumor xenografts. Infusion of low-affinity T-state PolyhHb led to increased tissue oxygenation, decreased blood flow, decreased tumor growth, and decreased vascularization in hypoxic tumors. However, infusion of both T-state and R-state PolyhHbs led to worse outcomes in normoxic tumors. Of particular concern was the high-affinity R-state PolyhHb, which led to no improvement in hypoxic tumors and significantly worsened outcomes in normoxic tumors. Taken together, the results of this study indicate that the tumor O2 status is a primary determinant of the potency and outcomes of infused PolyhHb.
- 19 June 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (12) , 2739-2750
Apohemoglobin-haptoglobin complexes attenuate the hypertensive response to low-molecular-weight polymerized hemoglobin
Polymerized hemoglobin (PolyHb) is a promising hemoglobin (Hb)-based oxygen carrier currently undergoing development as a red blood cell substitute. Unfortunately, commercially developed products are composed of low-molecular-weight (LMW) PolyHb molecules, which extravasate, scavenge nitric oxide, and result in vasoconstriction and hypertension. The naturally occurring Hb-scavenging species haptoglobin (Hp), combined with the purified heme-scavenging species apohemoglobin (apoHb), is a potential candidate to alleviate the pressor effect of PolyHb. This study evaluated the protective activity of administering the apoHb-Hp complex to mitigate the vasoactive response induced by the transfusion of LMW PolyHb. Hp binding to PolyHb was characterized in vitro. The effectiveness of apoHb–Hp administration on reducing the vasoconstriction and pressor effects of PolyHb was assessed by measuring systemic and microcirculatory hemodynamics. Transfusion of LMW PolyHb to vehicle control pretreated animals increased mean arterial pressure while decreasing arteriole diameter and functional capillary density. However, transfusion of LMW PolyHb to apoHb–Hp pretreated animals prevented changes in mean arterial pressure, heart rate, arteriole diameter, blood flow, and functional capillary density relative to before transfusion. These results indicate that the increased size of PolyHb after binding to the apoHb-Hp complex may help compartmentalize PolyHb in the vascular space and thus reduce extravasation, nitric oxide scavenging, and toxicity responsible for vasoconstriction and systemic hypertension.
- 19 June 2020
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (12) , 2739-2750
Apohemoglobin-haptoglobin complexes attenuate the hypertensive response to low-molecular-weight polymerized hemoglobin
Polymerized hemoglobin (PolyHb) is a promising hemoglobin (Hb)-based oxygen carrier currently undergoing development as a red blood cell substitute. Unfortunately, commercially developed products are composed of low-molecular-weight (LMW) PolyHb molecules, which extravasate, scavenge nitric oxide, and result in vasoconstriction and hypertension. The naturally occurring Hb-scavenging species haptoglobin (Hp), combined with the purified heme-scavenging species apohemoglobin (apoHb), is a potential candidate to alleviate the pressor effect of PolyHb. This study evaluated the protective activity of administering the apoHb-Hp complex to mitigate the vasoactive response induced by the transfusion of LMW PolyHb. Hp binding to PolyHb was characterized in vitro. The effectiveness of apoHb–Hp administration on reducing the vasoconstriction and pressor effects of PolyHb was assessed by measuring systemic and microcirculatory hemodynamics. Transfusion of LMW PolyHb to vehicle control pretreated animals increased mean arterial pressure while decreasing arteriole diameter and functional capillary density. However, transfusion of LMW PolyHb to apoHb–Hp pretreated animals prevented changes in mean arterial pressure, heart rate, arteriole diameter, blood flow, and functional capillary density relative to before transfusion. These results indicate that the increased size of PolyHb after binding to the apoHb-Hp complex may help compartmentalize PolyHb in the vascular space and thus reduce extravasation, nitric oxide scavenging, and toxicity responsible for vasoconstriction and systemic hypertension.
- 12 June 2020
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (8) , 2362-2376
Comprehensive characterization of tense and relaxed quaternary state glutaraldehyde polymerized bovine hemoglobin as a function of cross‐link density
Previously, our lab developed high molecular weight (MW) tense (T) quaternary state glutaraldehyde polymerized bovine hemoglobins (PolybHbs) that exhibited reduced vasoactivity in several small animal models. In this study, we prepared PolybHb in the T and relaxed (R) quaternary state with ultrahigh MW (>500 kDa) with varying cross‐link densities, and investigated the effect of MW on key biophysical properties (i.e., O2 affinity, cooperativity (Hill) coefficient, hydrodynamic diameter, polydispersity, polymer composition, viscosity, gaseous ligand‐binding kinetics, auto‐oxidation, and haptoglobin [Hp]‐binding kinetics). To further optimize current PolybHb synthesis and purification protocols, we performed a comprehensive meta‐data analysis to evaluate correlations between procedural parameters (i.e., cross‐linker:bovine hemoglobin (bHb) molar ratio, gas‐liquid exchange time, temperature during sodium dithionite addition, and number of diafiltration cycles) and the biophysical properties of both T‐ and R‐state PolybHbs. Our results showed that, the duration of the fast‐step auto‐oxidation phase of R‐state PolybHb increased with decreasing glutaraldehyde:bHb molar ratio. Additionally, T‐state PolybHbs exhibited significantly higher bimolecular rate constants for binding to Hp and unimolecular O2 offloading rate constants compared to R‐state PolybHbs. The methemoglobin (metHb) level in the final product was insensitive to the molar ratio of glutaraldehyde to bHb for all PolybHbs. During tangential flow filtration processing of the final product, 14 diafiltration cycles was found to yield the lowest metHb level.
- 12 June 2020
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (8) , 2362-2376
Comprehensive characterization of tense and relaxed quaternary state glutaraldehyde polymerized bovine hemoglobin as a function of cross‐link density
Previously, our lab developed high molecular weight (MW) tense (T) quaternary state glutaraldehyde polymerized bovine hemoglobins (PolybHbs) that exhibited reduced vasoactivity in several small animal models. In this study, we prepared PolybHb in the T and relaxed (R) quaternary state with ultrahigh MW (>500 kDa) with varying cross‐link densities, and investigated the effect of MW on key biophysical properties (i.e., O2 affinity, cooperativity (Hill) coefficient, hydrodynamic diameter, polydispersity, polymer composition, viscosity, gaseous ligand‐binding kinetics, auto‐oxidation, and haptoglobin [Hp]‐binding kinetics). To further optimize current PolybHb synthesis and purification protocols, we performed a comprehensive meta‐data analysis to evaluate correlations between procedural parameters (i.e., cross‐linker:bovine hemoglobin (bHb) molar ratio, gas‐liquid exchange time, temperature during sodium dithionite addition, and number of diafiltration cycles) and the biophysical properties of both T‐ and R‐state PolybHbs. Our results showed that, the duration of the fast‐step auto‐oxidation phase of R‐state PolybHb increased with decreasing glutaraldehyde:bHb molar ratio. Additionally, T‐state PolybHbs exhibited significantly higher bimolecular rate constants for binding to Hp and unimolecular O2 offloading rate constants compared to R‐state PolybHbs. The methemoglobin (metHb) level in the final product was insensitive to the molar ratio of glutaraldehyde to bHb for all PolybHbs. During tangential flow filtration processing of the final product, 14 diafiltration cycles was found to yield the lowest metHb level.
- 14 April 2020
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 3 (5) , 2976-2985
Polymerized Hemoglobin With Increased Molecular Size Reduces Toxicity in Healthy Guinea Pigs
Hemoglobin (Hb) based oxygen (O2) carriers (HBOCs) have been developed as an alternative to red blood cells (RBCs) for use in transfusion medicine. HBOCs have many benefits over RBCs; however, previous generations of HBOCs failed in clinical trials due to unanticipated cardiotoxicity. These problems likely originated from vasoconstriction, hypertension, oxidative stress, and the presence of low molecular weight (MW) Hb species in the HBOC formulation. Therefore, the objective of this study is to compare the toxicity of small MW PolyHb (SPolyHb) to large MW PolyHb (LPolyHb) in guinea pigs, since they lack the ability to synthesize vitamin C and are more sensitive to oxidative stress relative to other preclinical animal models. Study groups were defined by study solutions, and the control group received 5% human serum albumin (HSA). Solutions were injected as a hypervolemic (topload) infusion of 10% of the blood volume into animals. A set of animals was monitored for 2 hours, in terms of mean arterial pressure, heart rate, and blood gases; and another set of animals was monitored for 24 hours for pharmacokinetics. SPolyHb caused a 50% elevation in MAP from baseline, while LPolyHb caused only a small increase in MAP. Both PolyHbs also increased markers of organ damage, and tissue and systemic inflammation compared to controls. SPolyHb caused significant changes in tissue function and vital organ toxicity markers compared to LPolyHb, specifically markers related to kidney, liver, and lung injury, as well as systemic inflammation and iron transport by the reticuloendothelial system. LPolyHb had a longer half-life than SPolyHb, which correlates with the observations made in the reticuloendothelial and iron transport systems. These studies indicate that the molecular size of PolyHb determines vasoactivity, circulation time, mechanism of elimination, toxicity and inflammation induced by its infusion.
- 14 April 2020
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 3 (5) , 2976-2985
Polymerized Hemoglobin With Increased Molecular Size Reduces Toxicity in Healthy Guinea Pigs
Hemoglobin (Hb) based oxygen (O2) carriers (HBOCs) have been developed as an alternative to red blood cells (RBCs) for use in transfusion medicine. HBOCs have many benefits over RBCs; however, previous generations of HBOCs failed in clinical trials due to unanticipated cardiotoxicity. These problems likely originated from vasoconstriction, hypertension, oxidative stress, and the presence of low molecular weight (MW) Hb species in the HBOC formulation. Therefore, the objective of this study is to compare the toxicity of small MW PolyHb (SPolyHb) to large MW PolyHb (LPolyHb) in guinea pigs, since they lack the ability to synthesize vitamin C and are more sensitive to oxidative stress relative to other preclinical animal models. Study groups were defined by study solutions, and the control group received 5% human serum albumin (HSA). Solutions were injected as a hypervolemic (topload) infusion of 10% of the blood volume into animals. A set of animals was monitored for 2 hours, in terms of mean arterial pressure, heart rate, and blood gases; and another set of animals was monitored for 24 hours for pharmacokinetics. SPolyHb caused a 50% elevation in MAP from baseline, while LPolyHb caused only a small increase in MAP. Both PolyHbs also increased markers of organ damage, and tissue and systemic inflammation compared to controls. SPolyHb caused significant changes in tissue function and vital organ toxicity markers compared to LPolyHb, specifically markers related to kidney, liver, and lung injury, as well as systemic inflammation and iron transport by the reticuloendothelial system. LPolyHb had a longer half-life than SPolyHb, which correlates with the observations made in the reticuloendothelial and iron transport systems. These studies indicate that the molecular size of PolyHb determines vasoactivity, circulation time, mechanism of elimination, toxicity and inflammation induced by its infusion.
- Open Access
- 10 January 2020
- Published by Wiley in Biotechnology Progress
- Vol. 36 (3) , e2958
Next‐generation polymerized human hemoglobins in hepatic bioreactor simulations
Hepatic hollow fiber (HF) bioreactors can be used to provide temporary support to patients experiencing liver failure. Before being connected to the patient's circulation, cells in the bioreactor must be exposed to a range of physiological O 2 concentrations as observed in the liver sinusoid to ensure proper performance. This zonation in cellular oxygenation promotes differences in hepatocyte phenotype and may better approximate the performance of a real liver within the bioreactor. Polymerized human hemoglobin (PolyhHb) locked in the tense quaternary state (T‐state) has the potential to both supply and regulate O 2 transport to cultured hepatocytes in the bioreactor due to its low O 2 affinity. In this study, T‐state PolyhHb production and purification processes were optimized to minimize the concentration of low‐molecular‐weight PolyhHb species in solution. Deconvolution of size‐exclusion chromatography spectra was performed to calculate the distribution of polymeric Hb species in the final product. Fluid flow and mass transport within a single fiber of a hepatic HF bioreactor was computationally modeled with finite element methods to simulate the effects of employing T‐state PolyhHb to facilitate O 2 transport in a hepatic bioreactor system. Optimal bioreactor performance was defined as having a combined hypoxic and hyperoxic volume fraction in the extracapillary space of less than 0.05 where multiple zones were observed. The Damköhler number and Sherwood number had strong inverse relationships at each cell density and fiber thickness combination. These results suggest that targeting a specific Damköhler number may be beneficial for optimal hepatic HF bioreactor operation.
- 10 January 2020
- Published by Wiley in Biotechnology Progress
- Vol. 36 (3) , e2958
Open AccessNext‐generation polymerized human hemoglobins in hepatic bioreactor simulations
Hepatic hollow fiber (HF) bioreactors can be used to provide temporary support to patients experiencing liver failure. Before being connected to the patient's circulation, cells in the bioreactor must be exposed to a range of physiological O 2 concentrations as observed in the liver sinusoid to ensure proper performance. This zonation in cellular oxygenation promotes differences in hepatocyte phenotype and may better approximate the performance of a real liver within the bioreactor. Polymerized human hemoglobin (PolyhHb) locked in the tense quaternary state (T‐state) has the potential to both supply and regulate O 2 transport to cultured hepatocytes in the bioreactor due to its low O 2 affinity. In this study, T‐state PolyhHb production and purification processes were optimized to minimize the concentration of low‐molecular‐weight PolyhHb species in solution. Deconvolution of size‐exclusion chromatography spectra was performed to calculate the distribution of polymeric Hb species in the final product. Fluid flow and mass transport within a single fiber of a hepatic HF bioreactor was computationally modeled with finite element methods to simulate the effects of employing T‐state PolyhHb to facilitate O 2 transport in a hepatic bioreactor system. Optimal bioreactor performance was defined as having a combined hypoxic and hyperoxic volume fraction in the extracapillary space of less than 0.05 where multiple zones were observed. The Damköhler number and Sherwood number had strong inverse relationships at each cell density and fiber thickness combination. These results suggest that targeting a specific Damköhler number may be beneficial for optimal hepatic HF bioreactor operation.
- 23 December 2019
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 31 (3) , 605-621
Controlled Polymerization and Ultrafiltration Increase the Consistency of Polymerized Hemoglobin for Use as an Oxygen Carrier
Polymerized human hemoglobins (PolyhHb) are a promising class of red blood cell substitute for use in transfusion medicine. Unfortunately, application of the commonly used glutaraldehyde crosslinking chemistry that is employed to synthesize these materials results in a complex mixture of PolyhHb molecules with highly varied batch-to-batch consistency. In this work, we implemented a controlled method of gas exchange and reagent addition that results in a more homogenous PolyhHb product. A fully coupled bench-scale tangential flow filtration system was then used to purify and concentrate the synthesized PolyhHb molecules. We determined that this improved method of PolyhHb production could be used to more precisely control the size and reduce the polydispersity of PolyhHb molecules with minimal effects on the resulting PolyhHb oxygen-carrying capacity, oxygen affinity, and oxygen offloading characteristics. In addition to these factors, we assessed how the hemoglobin scavenging protein haptoglobin (Hp) would interact with PolyhHb molecules of varying size and quarternary state. Our results indicated that T-State PolyhHbs may be more efficiently detoxified by Hp compared to R-State PolyhHb and unmodified Hb.
- 23 December 2019
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 31 (3) , 605-621
Controlled Polymerization and Ultrafiltration Increase the Consistency of Polymerized Hemoglobin for Use as an Oxygen Carrier
Polymerized human hemoglobins (PolyhHb) are a promising class of red blood cell substitute for use in transfusion medicine. Unfortunately, application of the commonly used glutaraldehyde crosslinking chemistry that is employed to synthesize these materials results in a complex mixture of PolyhHb molecules with highly varied batch-to-batch consistency. In this work, we implemented a controlled method of gas exchange and reagent addition that results in a more homogenous PolyhHb product. A fully coupled bench-scale tangential flow filtration system was then used to purify and concentrate the synthesized PolyhHb molecules. We determined that this improved method of PolyhHb production could be used to more precisely control the size and reduce the polydispersity of PolyhHb molecules with minimal effects on the resulting PolyhHb oxygen-carrying capacity, oxygen affinity, and oxygen offloading characteristics. In addition to these factors, we assessed how the hemoglobin scavenging protein haptoglobin (Hp) would interact with PolyhHb molecules of varying size and quarternary state. Our results indicated that T-State PolyhHbs may be more efficiently detoxified by Hp compared to R-State PolyhHb and unmodified Hb.
- 10 December 2019
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (1)
Front Cover Image, Volume 117, Number 1, January 2020
- 10 December 2019
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (1)
Front Cover Image, Volume 117, Number 1, January 2020
- 15 October 2019
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (1) , 125-145
Novel manufacturing method for producing apohemoglobin and its biophysical properties
Apohemoglobin (apoHb) is a dimeric globular protein with two vacant heme‐binding pockets that can bind heme or other hydrophobic ligands. Purification of apoHb is based on partial hemoglobin (Hb) unfolding to facilitate heme extraction into an organic solvent. However, current production methods are time consuming, difficult to scale up, and use highly flammable and toxic solvents. In this study, a novel and scalable apoHb production method was developed using an acidified ethanol solution to extract the hydrophobic heme ligand into solution and tangential flow filtration to separate heme from the resultant apoprotein. Total protein and active protein yields were >95% and ~75%, respectively, with 99% purity from sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis. Virtually no loss of apoHb activity was detected at 4°C, −80°C, and in lyophilized form during long term storage. Structurally, size exclusion chromatography (SEC) and circular dichroism indicated that apoHb was dimeric with a ~25% reduction of helical content compared to Hb. Furthermore, mass spectroscopy and reverse‐phase chromatography indicated that the mass of the α and β subunits were virtually identical to the theoretical mass of these subunits in Hb and had no detectable oxidative modifications upon heme removal from Hb. SEC confirmed that apoHb bound to haptoglobin at a similar ratio to that of native Hb. Finally, reconstituted Hb (rHb) was processed via a hemichrome removal method to isolate functional rHb for biophysical characterization in which the O2 equilibrium curve, O2 dissociation, and CO association kinetics of rHb were virtually identical to native Hb. Overall, this study describes a novel and improved method to produce apoHb, as well as presents a comprehensive biochemical analysis of apoHb and rHb.
- 15 October 2019
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (1) , 125-145
Novel manufacturing method for producing apohemoglobin and its biophysical properties
Apohemoglobin (apoHb) is a dimeric globular protein with two vacant heme‐binding pockets that can bind heme or other hydrophobic ligands. Purification of apoHb is based on partial hemoglobin (Hb) unfolding to facilitate heme extraction into an organic solvent. However, current production methods are time consuming, difficult to scale up, and use highly flammable and toxic solvents. In this study, a novel and scalable apoHb production method was developed using an acidified ethanol solution to extract the hydrophobic heme ligand into solution and tangential flow filtration to separate heme from the resultant apoprotein. Total protein and active protein yields were >95% and ~75%, respectively, with 99% purity from sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis. Virtually no loss of apoHb activity was detected at 4°C, −80°C, and in lyophilized form during long term storage. Structurally, size exclusion chromatography (SEC) and circular dichroism indicated that apoHb was dimeric with a ~25% reduction of helical content compared to Hb. Furthermore, mass spectroscopy and reverse‐phase chromatography indicated that the mass of the α and β subunits were virtually identical to the theoretical mass of these subunits in Hb and had no detectable oxidative modifications upon heme removal from Hb. SEC confirmed that apoHb bound to haptoglobin at a similar ratio to that of native Hb. Finally, reconstituted Hb (rHb) was processed via a hemichrome removal method to isolate functional rHb for biophysical characterization in which the O2 equilibrium curve, O2 dissociation, and CO association kinetics of rHb were virtually identical to native Hb. Overall, this study describes a novel and improved method to produce apoHb, as well as presents a comprehensive biochemical analysis of apoHb and rHb.